Align Technology
ALGN
$190.07
+2.73%
Align Technology Inc. is a leading healthcare company specializing in medical devices, most notably the Invisalign system of clear aligners and the iTero line of intraoral scanners. The company holds a dominant market position, controlling over 90% of the clear aligner market and boasting a network of over 230,000 trained dental professionals. The current investor narrative is heavily influenced by activist investor involvement, with a recent report of a large position by Elliott Management providing a catalyst for the stock as the market debates the potential for operational improvements and value unlocking, against the backdrop of the company's ongoing efforts to drive adoption of its digital orthodontic platform.…
ALGN
Align Technology
$190.07
Related headlines
Investment Opinion: Should I buy ALGN Today?
Rating & Thesis: Hold. ALGN presents a balanced risk/reward profile where compelling forward valuation and a potent activist catalyst are offset by slowing growth, high volatility, and earnings uncertainty. The recent analyst upgrades (HSBC to Buy, Barclays to Overweight) reflect optimism around the Elliott position, but insufficient consensus data prevents a strong directional call.
Supporting Evidence: The primary valuation metric, the forward PE of 14.1x, is attractive for a market leader and implies significant earnings growth from the consensus EPS estimate of $15.71. The company's financial health is exceptional, with a robust current ratio of 1.36 and $593 million in TTM free cash flow. Profitability rebounded strongly in Q4 with a 13.0% net margin, and gross margins remain high at 68.3% TTM. However, revenue growth is modest at 5.26% YoY, and the stock's high beta of 1.81 signals substantial volatility risk that tempers the valuation appeal.
Risks & Conditions: The two biggest risks are 1) failure of revenue growth to re-accelerate above 10%, leading to multiple compression, and 2) the activist catalyst failing to materialize into tangible operational improvements or shareholder returns. This Hold rating would upgrade to a Buy if the forward PE compresses further toward 12x on temporary weakness, or if Q1 2026 revenue growth accelerates above 8% YoY. It would downgrade to a Sell if revenue growth decelerates below 3% or if gross margins fall sustainably below 65%. Relative to its own history and sector peers, the stock appears fairly valued, pricing in a moderate growth recovery but not perfection.
Sign up to view all
ALGN 12-Month Price Forecast
ALGN is a classic 'show me' story at a crossroads. The valuation is undemanding on a forward basis, and the balance sheet is fortress-like, but the market needs to see proof that growth can re-accelerate beyond the current low-single-digit pace. The activist involvement adds a fascinating optionality that skews potential outcomes positively but is binary in nature. The high volatility is a significant headwind for all but the most risk-tolerant investors. The stance would upgrade to Bullish on confirmation of sustained revenue growth above 7% or a clear capital return plan from the activist engagement. It would downgrade to Bearish on a breakdown below key technical support at $150 coupled with decelerating growth.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Align Technology's 12-month outlook, with a consensus price target around $247.09 and implied upside of +30.0% versus the current price.
Average Target
$247.09
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$152 - $247
Analyst target range
Analyst coverage for ALGN appears limited based on the provided data, with only 7 analysts contributing to estimates for revenue and EPS. The data does not include a consensus recommendation, average price target, or target range, indicating insufficient analyst coverage is available for a full sentiment analysis. This limited coverage, despite the company's $11.3 billion market cap, could be due to its niche within the medical devices sector and may contribute to higher volatility and less efficient price discovery as the stock reacts more to specific catalysts, like the recent activist investor news, rather than a steady stream of analyst updates. The recent institutional rating actions show a generally positive bias, with upgrades from HSBC (Hold to Buy) and Barclays (Equal Weight to Overweight) in early 2026, alongside reaffirmations of Buy/Outperform ratings from firms like Stifel, Evercore ISI, Wells Fargo, and Piper Sandler.
Bulls vs Bears: ALGN Investment Factors
The bull and bear cases for ALGN are closely balanced, with the bull side currently holding a slight edge due to the potent activist catalyst and compelling forward valuation. The strongest bull arguments center on Elliott Management's involvement potentially unlocking value and the stock's attractive 14.1x forward PE, which prices in a significant earnings recovery. The most compelling bear points highlight the stock's high volatility (beta 1.81) and its struggle to accelerate revenue growth beyond a modest 5.26% pace. The single most important tension in the investment debate is whether activist pressure and operational improvements can successfully re-accelerate growth to justify the forward earnings multiple, or if the company's dominant market position has naturally led to a maturation phase of single-digit growth, leaving the stock vulnerable to de-rating. The resolution of this growth trajectory question will likely determine the stock's direction over the next 12 months.
Bullish
- Activist Catalyst from Elliott Management: The recent report of a large position by activist investor Elliott Management provides a powerful catalyst for potential operational improvements and value unlocking. This external pressure could accelerate strategic changes, such as cost rationalization or capital return, that the market has not fully priced in, especially given the stock's recovery from 52-week lows.
- Strong Profitability & Cash Flow Rebound: Q4 2025 net income of $135.8 million represents a significant rebound from Q3's $56.8 million, with net margin improving from 5.7% to 13.0%. The company generates robust free cash flow of $593.2 million TTM, funding growth and buybacks without reliance on debt, as evidenced by a minimal debt-to-equity ratio of 0.028.
- Compelling Forward Valuation at 14.1x PE: The forward PE of 14.1x is nearly half the trailing PE of 27.6x, implying the market expects significant earnings growth. This forward multiple is attractive for a company with a dominant 90% market share, high gross margins (68.3% TTM), and a strong balance sheet, suggesting the stock is pricing in a normalized, not hyper-growth, scenario.
- Dominant Market Position & High Barriers: Align controls over 90% of the clear aligner market with a network of 230,000 trained professionals, creating a formidable moat. The iTero scanner ecosystem, used in over half of digital case submissions, further entrenches its digital platform, making competitive disruption difficult and supporting long-term pricing power.
Bearish
- Slowing Single-Digit Revenue Growth: Q4 2025 revenue grew only 5.26% YoY to $1.05B, continuing a trend of stable, single-digit growth over recent quarters. This modest pace, from a dominant market position, raises questions about the company's ability to re-accelerate top-line expansion and meet heightened investor expectations embedded in the forward valuation.
- High Volatility & Market Underperformance: With a beta of 1.81, ALGN is 81% more volatile than the broader market, leading to sharp drawdowns like the -39.73% max drawdown. It has significantly underperformed the S&P 500 over the past year, with a relative strength of -21.4%, indicating weak momentum and high sensitivity to market sentiment shifts.
- Valuation Premium & Earnings Volatility: The trailing PE of 27.6x trades at a premium to the sector, yet earnings have been volatile, as seen in the Q3 to Q4 net income swing. The high PEG ratio of 51.8 signals the stock is expensive relative to its near-term growth prospects, making it vulnerable to multiple compression if growth disappoints.
- Limited Analyst Coverage & Visibility: Only 7 analysts cover the stock, limiting consensus data and potentially contributing to inefficient price discovery and higher volatility. The lack of a clear average price target or strong consensus reduces investor confidence and increases reliance on singular catalysts like activist news for price movement.
ALGN Technical Analysis
The stock is in a strong recovery phase from its 52-week lows, evidenced by a 1-year price change of +8.12% and a more pronounced 6-month surge of +37.64%. Currently trading at $173.14, the price sits approximately 34% above its 52-week low of $122.00 but remains 17% below its 52-week high of $208.31, indicating it has recovered from the lows but still has significant room to recapture prior highs. Recent momentum shows a short-term consolidation, with the stock down 0.96% over the past month and up a modest 0.20% over the past three months, suggesting a pause after the sharp rally from late 2025 into early 2026. This divergence from the strong 6-month uptrend could signal a healthy pullback or consolidation before a potential next leg higher. Key technical levels are clearly defined by the 52-week high of $208.31 as major resistance and the 52-week low of $122.00 as critical support. A breakout above resistance would signal a resumption of the bullish trend, while a breakdown below support would invalidate the recovery thesis. The stock exhibits high volatility with a beta of 1.81, meaning it is approximately 81% more volatile than the broader market, which investors must account for in position sizing and risk management.
Beta
1.81
1.81x market volatility
Max Drawdown
-39.7%
Largest decline past year
52-Week Range
$122-$208
Price range past year
Annual Return
+10.9%
Cumulative gain past year
| Period | ALGN Return | S&P 500 |
|---|---|---|
| 1m | +10.2% | +7.4% |
| 3m | +10.8% | +2.7% |
| 6m | +45.7% | +6.9% |
| 1y | +10.9% | +34.9% |
| ytd | +21.8% | +4.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALGN Fundamental Analysis
Revenue growth has been positive but modest, with Q4 2025 revenue of $1.05 billion representing a 5.26% year-over-year increase. Segment data shows the Clear Aligner business, at $794.3 million, remains the primary growth driver, significantly larger than the Scanners and Services segment at $200.9 million. The multi-quarter trend shows revenue has been relatively stable in the $0.98-$1.05 billion range over the past two years, indicating a period of steady, single-digit growth rather than rapid acceleration. The company is solidly profitable, with Q4 2025 net income of $135.8 million and a net margin of 12.96%. Gross margin for the quarter was a healthy 65.69%, though it has fluctuated between 64% and 70% in recent quarters, reflecting potential product mix or cost pressures. Profitability has shown improvement from the weaker Q3 2025, where net income was $56.8 million with a 5.7% net margin, suggesting a rebound in earnings power. The balance sheet is exceptionally strong with minimal financial risk, featuring a very low debt-to-equity ratio of 0.028 and a robust current ratio of 1.36. The company generates substantial cash, with trailing twelve-month free cash flow of $593.2 million, providing ample internal funding for growth initiatives and share repurchases without reliance on external debt.
Quarterly Revenue
$1.0B
2025-12
Revenue YoY Growth
+0.05%
YoY Comparison
Gross Margin
+0.65%
Latest Quarter
Free Cash Flow
$593223000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALGN Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio stands at 27.6x, while the forward PE is significantly lower at 14.1x. This substantial gap implies the market expects a meaningful earnings recovery or growth in the coming year, as the forward multiple prices in the analyst consensus EPS estimate of $15.71. Compared to sector averages, Align's trailing PE of 27.6x trades at a premium; however, a direct industry average is not provided in the data for a quantified spread. This premium is likely justified by its dominant market position, high gross margins (68.3% TTM), and the growth potential of its digital orthodontic platform. Historically, the stock's own valuation has compressed significantly from pandemic-era highs. The current trailing PE of 27.6x is well below its historical peaks above 70x seen in 2021-2022 and is more in line with its mid-to-high 20s range observed in late 2023 and 2025. Trading near the middle of its own historical band suggests the market is pricing in a more normalized growth profile rather than the hyper-growth expectations of prior years.
PE
27.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 21x~98x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Align's primary financial risk is not leverage—its balance sheet is pristine with a 0.028 debt-to-equity ratio—but rather earnings volatility and growth deceleration. Net income swung from $56.8 million in Q3 2025 to $135.8 million in Q4, demonstrating quarter-to-quarter unpredictability that complicates valuation. Furthermore, revenue growth has stabilized in the low-to-mid single digits (5.26% YoY in Q4), raising concerns that the company's dominant market share may limit future expansion without significant new product adoption or geographic penetration. Gross margin fluctuation between 64% and 70% adds another layer of operational risk, as sustained pressure could erode the high profitability that supports its premium valuation.
Market & Competitive Risks: The stock trades at a trailing PE premium (27.6x) to the healthcare sector, making it susceptible to valuation compression if growth stock multiples contract or if earnings fail to meet the high expectations implied by its forward PE of 14.1x. Its high beta of 1.81 indicates extreme sensitivity to broader market swings, often underperforming in risk-off environments as seen in its -21.4% relative strength vs. the S&P 500 over the past year. While direct competitive disruption is limited due to its 90% market share, the risk lies in market saturation or a slowdown in discretionary orthodontic spending during economic downturns, which could immediately impact its volume-based revenue model.
Worst-Case Scenario: The most damaging scenario involves a combination of activist engagement failing to produce tangible results, a macroeconomic slowdown reducing discretionary dental care spending, and a subsequent earnings miss triggering multiple compression. In this adverse scenario, the stock could re-test its 52-week low of $122, representing a -29.5% downside from the current price of $173.14. A further deterioration, potentially to levels seen during past drawdowns (the max drawdown is -39.73%), could push the stock toward $105, a -39% decline. The high short ratio of 2.45 indicates a skeptical investor base that could amplify selling pressure if the thesis unravels.
FAQ
The key risks are, in order of severity: 1) Growth Deceleration: Revenue growth has slowed to 5.26% YoY; further slowing could crush the forward earnings multiple. 2) Extreme Volatility: With a beta of 1.81, the stock is highly sensitive to market swings, leading to a max drawdown of -39.73%. 3) Activist Catalyst Failure: If Elliott Management's involvement does not lead to tangible value creation, a key support for the recent rally vanishes. 4) Margin Erosion: Fluctuating gross margins (65.7% in Q4 2025) create earnings uncertainty and could pressure the premium valuation if they trend lower.
Our 12-month forecast outlines three scenarios. The Base Case (50% probability) sees the stock trading between $170 and $195, assuming steady execution and mid-single-digit growth. The Bull Case (30% probability) targets $208 to $230, driven by successful activist engagement and re-accelerated growth. The Bear Case (20% probability) sees a drop to $122-$150 on growth disappointment and multiple compression. The Base Case is most likely, anchored by the achievable consensus EPS of $15.71 and the current forward PE. The key assumption is that revenue growth stabilizes and does not decelerate further.
ALGN appears fairly valued relative to its near-term prospects. The trailing PE of 27.6x is at a premium to the sector, but the forward PE of 14.1x is much more reasonable, implying the market expects significant earnings growth to a consensus EPS of $15.71. Compared to its own history, the current multiple is well below pandemic-era highs above 70x and sits in a normalized range. The valuation implies the market is paying a fair price for a leader in a steady, single-digit growth phase, with a discount for uncertainty. It is not deeply undervalued, nor is it egregiously overvalued.
ALGN is a conditional buy for investors comfortable with high volatility and speculative catalysts. The forward PE of 14.1x is attractive for a market leader, and the activist stake by Elliott Management provides a tangible catalyst for upside. However, the stock's high beta of 1.81 means it is 81% more volatile than the market, and revenue growth remains modest at 5.26%. It is a good buy for growth investors seeking exposure to a dominant healthcare tech name with a favorable risk/reward skew, but only if they can tolerate the potential for a -30% drawdown to the 52-week low of $122.
ALGN is more suitable for a medium-to-long-term investment horizon of 12-24 months, not short-term trading. The company's growth story and the activist catalyst will take multiple quarters to play out, and the high beta of 1.81 makes short-term price movements highly unpredictable. Long-term investors can benefit from the company's durable competitive moat and cash generation, while weathering volatility. There is no dividend, eliminating it as an income stock. A minimum holding period of one year is suggested to allow the fundamental thesis and activist narrative to develop.